EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study

Michael Wang iD, Wojciech Jurczak, Marek Trneny iD, David Belada, Tomasz Wrobel iD, Nilanjan Ghosh iD, Mary-Margaret Keating, Tom van Meerten iD, Ruben Fernandez Alvarez, Gottfried von Keudell, Catherine Thieblemont, Frederic Peyrade und 7 weitere

British Journal of Haematology · 2026-08 · 209 (2) · 734-739

DOI: 10.1111/bjh.70620 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 12.07.2026. Verfasst von Michael Wang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie, Janssen Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

ibrutinibmantle cell lymphomavenetoclax

Autor:innen und Institutionen

  • Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Clinical Oncology, Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, Poland.
  • First Department of Internal Medicine - Hematology, General University Hospital in Prague, Prague, Czech Republic.
  • 4th Department of Internal Medicine - Haematology, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic.
  • Department of Medicine, Wrocław Medical University, Wrocław, Poland.
  • Department of Hematology, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA.

ORCID-Profile: Michael Wang, Marek Trneny, Tomasz Wrobel, Nilanjan Ghosh, Tom van Meerten, Constantine S Tam

Förderung

  • AbbVie
  • Janssen Research and Development

Zitieren

APA

Wang, M., Jurczak, W., Trneny, M., Belada, D., Wrobel, T., Ghosh, N., Keating, M. M., van Meerten, T., Alvarez, R. F., von Keudell, G., Thieblemont, C., Peyrade, F., Andre, M., Hoffmann, M., Szafer-Glusman, E., Lin, J., Dean, J. P., Neuenburg, J. K., & Tam, C. S. (2026). Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study. British Journal of Haematology, 209(2), 734-739. https://doi.org/10.1111/bjh.70620

Vancouver

Wang M, Jurczak W, Trneny M, Belada D, Wrobel T, Ghosh N, et al. Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study. British Journal of Haematology. 2026;209(2):734-739. doi:10.1111/bjh.70620

BibTeX
@article{Wang2026,
  author = {Wang, Michael and Jurczak, Wojciech and Trneny, Marek and Belada, David and Wrobel, Tomasz and Ghosh, Nilanjan and Keating, Mary-Margaret and van Meerten, Tom and Alvarez, Ruben Fernandez and von Keudell, Gottfried and Thieblemont, Catherine and Peyrade, Frederic and Andre, Marc and Hoffmann, Marc and Szafer-Glusman, Edith and Lin, Jennifer and Dean, James P and Neuenburg, Jutta K and Tam, Constantine S},
  title = {Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study},
  journal = {British Journal of Haematology},
  year = {2026},
  volume = {209},
  number = {2},
  pages = {734--739},
  doi = {10.1111/bjh.70620}
}
Kostenlos starten →